Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2007

Ablynx and Boehringer Ingelheim Embark on $265M Alzeimer’s Collaboration

  • Boehringer Ingelheim and Ablynx inked a deal worth almost $265 million to discover and develop new therapies for Alzheimer’s disease. The worldwide collaboration and license agreement will use Ablynx’ Nanobodies®, a novel class of therapeutic proteins.

    In addition Boehringer Ingelheim will commence a joint research program with Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture, and commercialization of any products resulting from the collaboration. The deal includes an upfront fee, development and commercial milestones., and sales-based royalties.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »